文献速递间质性肺疾病

抗中性粒细胞胞质抗体阳性的间质性肺疾病患者的临床特征及预后

[The clinical features and prognosis of interstitial lung disease patients with positive anti-neutrophil cytoplasmic antibody].
PubMed 文献 · Zhonghua Jie He He Hu Xi Za Zhi · 2020-01-01

本研究回顾性纳入北京协和医院274例间质性肺疾病患者,其中ANCA阳性38例(14%)。ANCA阳性患者发病年龄更高、血红蛋白更低、ESR更高,治疗后肺功能改善率和CT病变吸收率更低,病死率更高。结论提示ANCA阳性间质性肺疾病患者治疗效果不佳、预后较差。

要点

  • ANCA阳性间质性肺疾病患者发病年龄更高、炎症指标更高。
  • ANCA阳性患者治疗后肺功能改善率和CT病变吸收率更低。
  • ANCA阳性患者病死率高于CTD-ILD/IPAF和IIP组。

核心结论

  • ANCA阳性间质性肺疾病患者与其他类型间质性肺疾病患者在临床特征上存在显著差异,治疗效果不佳且预后较差。

研究设计与样本

  • 回顾性纳入2006年3月至2016年3月就诊于北京协和医院的间质性肺疾病患者274例,分为ANCA-ILD、CTD-ILD/IPAF和IIP三组进行分析。

主要发现

  • 274例患者中ANCA阳性38例(14%),其中男16例、女22例,年龄(59±10)岁,随访时间(52±31)个月,死亡7例(18.42%)。
  • ANCA-ILD组发病年龄高于CTD-ILD/IPAF组(52±10)岁和IIP组(53±11)岁,H=19.29,P<0.001。
  • ANCA-ILD组血红蛋白低于CTD-ILD/IPAF组和IIP组,H=8.17,P=0.017;ESR高于两组,H=19.73,P<0.001。
  • ANCA-ILD组治疗后肺功能FVC改善率31%低于CTD-ILD/IPAF组59%和IIP组39%,χ²=11.74,P=0.003。
  • ANCA-ILD组胸部CT病变吸收率61%低于CTD-ILD/IPAF组82%和IIP组67%,χ²=9.23,P=0.010;病死率18%高于CTD-ILD/IPAF组6%和IIP组12%,χ²=7.16,P=0.028。

临床怎么用

  • 对间质性肺疾病患者应检测ANCA以识别ANCA阳性亚型,该类患者治疗反应和预后较差,需加强监测与随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the clinical features and prognosis of interstitial lung disease patients with positive anti-neutrophil cytoplasmic antibody. Methods: The patients with interstitial lung disease who visited Peking Union Medical College Hospital from March 2006 to March 2016 were divided into three groups: interstitial lung disease with ANCA-positive(ANCA-ILD), connective tissue disease associated interstitial lung disease and interstitial pneumonia with autoimmune features (CTD-ILD/IPAF) and idiopathic interstitial pneumonia (IIP). The three groups were analyzed in terms of clinical manifestations, serology, lung function, imaging, survival and recurrence. Results: Two hundred and seventy four patients were enrolled and 38 (14%) were ANCA-positive of whom 16 were male and 22 were female. The age of 38 ANCA-positive patients was (59±10) years and the follow-up time was (52±31) months. Seven among the 38 ANCA-positive patients died and the death rate is 18.42%. The ANCA-positive patients with interstitial lung disease have higher onset age (ANCA-ILD:59±10,CTD-ILD/IPAF:52±10,IIP:53±11,H=19.29, P<0.001), lower hemoglobin (ANCA-ILD: 129±21, CTD-ILD/IPAF: 138±15, IIP: 140±19, H=8.17, P=0.017), higher erythrocyte sedimentation rate (ANCA-ILD:45±35, CTD-ILD/IPAF:26±24,IIP:19±22,H=19.73, P<0.001), lower lung function improvement rate after treatment (ANCA-ILD:31%,CTD-ILD/IPAF:59%,IIP: 39%,χ(2)=11.74,P=0.003), lower absorption rate of CT lesion (ANCA-ILD:61%,CTD-ILD/IPAF:82%,IIP:67%, χ(2)=9.23,P=0.010) and higher death rate(ANCA-ILD:18%,CTD-ILD/IPAF:6%,IIP:12%, χ(2)=7.16,P=0.028). Conclusions: There are significant differences in clinical characteristics between ANCA-positive patients and other types of pulmonary interstitial disease. And both the treatment effect and the prognosis is poor for the ANCA-positive patients. 目的: 探究血清抗中性粒细胞胞质抗体(ANCA)阳性的间质性肺疾病患者的临床特点及预后。 方法: 回顾性纳入2006年3月至2016年3月就诊于北京协和医院的间质性肺疾病患者274例,其中男81例,女193例,年龄(53±11)岁,根据诊断分为血清ANCA阳性肺间质病(ANCA-ILD)、结缔组织病相关性肺间质病和自身免疫特征的间质性肺炎(CTD-ILD/IPAF)及特发性间质性肺炎(IIP)组,分析3组患者在临床表现、血清学、肺功能、影像学、生存及复发方面的差异。 结果: 274例患者中ANCA阳性38例(38/274,14%),发病年龄(59±10)岁,随访时间(52±31)个月,死亡7例(7/38,18%)。ANCA阳性患者发病年龄高于CTD-ILD/IPAF[(52±10)岁]和IIP[(53±11)岁,H=19.29,P<0.001],血红蛋白[(129±21)mg/L]低于CTD-ILD/IPAF[(138±15)mg/L]和IIP[(140±19)mg/L,H=8.17,P=0.017],ESR[(46±35)mm/1 h]高于CTD-ILD/IPAF[(26±24)mm/1 h]和IIP[(19±22)mm/1 h,H=19.73,P<0.001],治疗后肺功能FVC改善率(31%)低于CTD-ILD/IPAF(59%)和IIP(39%,χ(2)=11.74,P=0.003),胸部CT病变吸收率(61%)低于CTD-ILD/IPAF(82%)和IIP(67%,χ(2)=9.23,P=0.010),病死率(18%)高于CTD-ILD/IPAF(6%)和IIP(12%, χ(2)=7.16,P=0.028)。 结论: ANCA阳性患者与其他类型肺间质病患者在临床特征方面存在差异,治疗效果不佳,预后较差。.

来源:Zhonghua Jie He He Hu Xi Za Zhi,查看原文。版权归原作者所有。

引用

  1. Gao C, Sun X, Huang J, et al. [The clinical features and prognosis of interstitial lung disease patients with positive anti-neutrophil cytoplasmic antibody]. Zhonghua Jie He He Hu Xi Za Zhi. 2020. PMID: 32294819. doi:10.3760/cma.j.cn112147-20191205-00813

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。